Ulixertinib for glioma driven by MAPK pathway
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests ulixertinib (a targeted pill) to see how well it works for certain gliomas driven by the MAPK/RAF-MEK-ERK signaling pathway. It also looks at whether the drug can help control tumor growth around the time of treatment planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) can give informed consent; children 12+ can be included with added consent steps.
- You are age 18+ for non-child dosing, or age 12+ for the pediatric group; pediatric dosing requires body size (BSA) of 0.9 or more.
- Your tumor diagnosis is a MAPK-activated glioma or related brain tumor, based on special lab testing of tumor tissue.
- You had a prior brain surgery/biopsy that confirmed glioma, and you must have tumor tissue stored for testing (archival tissue).
- Your scans must show progressive (worsening) disease, and you meet health/lab requirements (including heart function and blood counts).
- If you recently had radiation, you must be at least 12 weeks out (steroids must be stable or decreasing before screening).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug ulixertinib, combined with cetuximab (and sometimes encorafenib), can help people with advanced or metastatic colorectal cancer who have already tried EGFR or BRAF-targeted therapy. It aims to find new treatment options for these patients.
This trial offers access to ulixertinib, an oral drug that targets specific genetic changes (MAPK pathway) in advanced cancers. It is for people who have run out of standard options and may benefit from this targeted treatment.
This trial tests an oral targeted therapy called ulixertinib for people with histiocytic neoplasms (a rare group of blood cell disorders). It aims to see if the drug can shrink tumors or control the disease in patients who have not responded to other treatments.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
This trial tests a new targeted medicine (FCN-159) against standard chemotherapy for children with slow-growing brain or nervous system tumors that have a specific genetic change (BRAF alteration). The goal is to see if the new pill works better at shrinking or controlling the tumor.
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Hear when a new Gliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.